LAUSR

Coronavirus disease-2019 (COVID-19), causes mild illness to serious infection with lung involvement, thrombosis and other complications potentially resulting in fatal outcome. Recognised inflammatory biomarkers play important roles in the management of patients with COVID-19; for example, diagnosis, follow-up, assessment of treatment response and risk stratification. Inflammatory markers in COVID-19 disease were analysed in two categories. Well-known inflammatory markers included complete blood count, C-reactive protein, albumin, cytokines and erythrocyte sedimentation rate. Asymmetric dimethylarginine, endocan, pentraxin 3, serum amyloid A, soluble urokinase plasminogen activator receptor, total oxidant status and total antioxidant status, galectin-3 were considered among the emerging inflammatory markers. This brief narrative review assesses the relationship between these inflammatory markers and COVID-19 infection.